Can-Fite Secures Japan Patent for Oral Obesity Therapy Namodenoson
CANF•Japan Patent Office granted Can-Fite Patent No. 2025-049941 covering A3 adenosine receptor agonists, including Namodenoson, for inducing fat loss and treating obesity in Japan. This allowance further strengthens its international exclusivity following approvals in the US, Canada, Australia and Israel, bolstering partnership prospects in a $60 billion obesity market.
1. Japan Patent Approval
The Japan Patent Office has allowed application No. 2025-049941, a divisional of JP 2023-078136, covering A3 adenosine receptor agonists including Namodenoson for inducing fat loss and treating obesity and related metabolic disorders in Japan.
2. Expansion of Global Patent Portfolio
This allowance adds to existing patents in the US, Canada, Australia and Israel, creating a robust intellectual property estate that secures exclusive rights in major pharmaceutical markets and enhances Can-Fite’s appeal for licensing and partnership discussions.
3. Therapeutic Potential and Market Outlook
Namodenoson is an oral, highly selective A3AR agonist with clinical safety data that targets adipogenesis, inflammation and metabolic regulation, offering a differentiated mechanism versus injectable GLP-1 therapies in a market projected to exceed $60 billion by 2030.
